Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global mycobacterium tuberculosis treatment market, valued at US$ 2.15 billion in 2024, is poised for steady growth, according to a comprehensive study by Fairfield Market Research. The market is expected to approximately US$ 2.4 billion by the end of 2031.
Challenges Posed by Tuberculosis
Tuberculosis remains a pressing global health issue, with 1.6 million deaths reported worldwide in 2021, making it the second leading infectious killer globally, following COVID-19 and HIV/AIDS. There were approximately 10.6 million reported cases of tuberculosis in 2021, affecting people of all ages.
The COVID-19 pandemic had a significant impact on tuberculosis diagnosis and treatment in 2020, leading to a 21% decline in TB treatment compared to 2019. Restrictions on movement, resource reallocation, and insufficient equipment and capacity hampered the provision of tuberculosis services.
Despite these challenges, the market for mycobacterium tuberculosis treatment is set to exhibit growth over the coming years. Government initiatives and National Strategic Plans aimed at eradicating tuberculosis by 2025 are expected to fuel steady growth in the market.
Growth Opportunities for Mycobacterium Tuberculosis Drug Manufacturers
• Rising Incidence of Multi-Drug Resistant Tuberculosis (MDR-TB): The prevalence of MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) is expected to increase in developing nations. Global initiatives like the WHO's Directly Observed Therapy (DOT) program are addressing the challenge of antimicrobial drug resistance in mycobacterium TB strains.
• Advancements in Novel Therapeutics and International Funding: Ongoing advancements in technology and the development of novel therapeutics are anticipated to shorten tuberculosis treatment duration and reduce its occurrence. International donor funding, including contributions to the Global Fund, remains crucial for low- and middle-income countries to combat tuberculosis effectively.
Market Progress and Competition
The availability of generic alternatives to tuberculosis medications has led to a wide range of low-cost prescription options. As branded pharmaceuticals lose patent protection, pharmaceutical companies face competition from generic drugs. This competition is expected to increase as more drugs enter the market, impacting manufacturers of original products.
Country-wise Insights
United States: The U.S. is a significant player in the global Mycobacterium Tuberculosis Treatment Market. The incidence of tuberculosis has been on the rise among both U.S.-born and non-U.S.-born individuals, contributing to market growth. The U.S. government is a major contributor to international funding for TB programs, which further supports market development.
China: China is emerging as a prominent market for Mycobacterium Tuberculosis drug suppliers in East Asia. The country has a high burden of latent tuberculosis infection (LTBI), with millions of people at risk for active TB illness. The Chinese government has initiated programs like the Healthy China Initiative 2024–2031, including Tuberculosis Control Action, which is expected to drive market growth.
India: India has a significant share of the South Asian market for Mycobacterium Tuberculosis treatment. The country has a high prevalence of tuberculosis and drug-resistant tuberculosis (MDR-TB). The incidence of tuberculosis has been increasing, and there are ongoing digital initiatives, such as #BeTheChangeForTB, supported by government and international agencies, to combat the disease.
Competitive Analysis
Key players in the mycobacterium tuberculosis treatment industry are actively engaged in activities such as new product launches, acquisitions, collaborations, and expansion to advance and develop new products and therapies.
Key Companies Profiled
• AstraZeneca
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Allergan
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Cipla Inc.
• Endo International plc
• Otsuka Pharmaceutical Co., Ltd.
• STI Pharma, LLC
Key Segments of Mycobacterium Tuberculosis Treatment Industry Research
By Disease Type:
• Latent TB
• Active TB
By Treatment Type:
• First-Line of Drugs
• Second-Line of Drugs
By Route of Administration:
• Oral
• Intravenous
• Intramuscular
By Distribution Channel:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Institutional and Retail Sales
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.